2017 Gund-Harrington Scholars

June 7, 2017

The Harrington Project for Discovery & Development

To:       University Hospitals Cleveland Medical Center Faculty Physicians

From:   Mukesh K. Jain, MD, FAHA
             Chief Scientific Officer, Harrington Discovery Institute
             Chief Scientific Officer, University Hospitals

Date:     June 7, 2017


The Harrington Discovery Institute at University Hospitals – part of The Harrington Project for Discovery & Development – has announced the 2017 scholars selected in collaboration with Foundation Fighting Blindness.

This is the third year of an affiliation with Foundation Fighting Blindness, founded by Gordon Gund. Gund-Harrington Scholars are selected for their outstanding research programs to slow, prevent or cure blindness. The 2017 award winners are:

  • Shannon Boye, PhD, University of Florida, for work in retinal degeneration and development of a novel therapy for Usher Syndrome 1B
  • Thomas Reh, PhD, University of Washington, for developing an orally bioavailable drug for the treatment of retinitis pigmentosa
  • Shigemi Matsuyama, PhD, Case Western Reserve University, for inhibitors of retinal cell death that treat a wide range of retinal degenerative diseases
  • Richard Kramer, PhD, University of California Berkeley, for studies of retinal degeneration and a photoswitch drug to treat retinitis pigmentosa

In addition to funding, award recipients receive committed drug development support and strategic advice through the Harrington Discovery Institute’s Innovation Support Center and the Foundation Fighting Blindness Clinical Research Institute for the duration of the term of the award. This includes consulting and management services from experienced pharmaceutical development professionals, as well as regulatory, intellectual property and business development assistance.

Harrington Scholars have facilitated access to BioMotiv – part of The Harrington Project for Discovery & Development – a for-profit commercialization company that is aligned with the Harrington Discovery Institute in mission and structure. BioMotiv was created to further advance discoveries by academic researchers in areas of unmet need.

Please join me in congratulating our newest Harrington Scholars as they advance their discoveries to benefit patients worldwide.

Important Links & Numbers

Refer A Patient

Call Direct 866-UH4-CARE (866-844-2273)
or 800-552-8338


Transfer Referral Line

216-844-1111 or
800-421-9199


UH Physician Portal


Find a UH Facility


Contact a UH Physician Liaison Team Member Direct
(216) 286-9024